{"filings":[{"id":697596,"accession_number":"0001493152-26-025441","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2026-05-27T20:57:37+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Dermata shareholders approve 2021 equity plan increase to 402,214 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected David Hale, Steven Mento Ph.D., and Brittany Bradrick as Class II directors.","Ratified CBIZ CPAs P.C. as independent auditor for FY2026.","Approved issuance of shares underlying warrants (exceeding 20% of outstanding common stock).","Approved repricing of warrants exercisable for up to 120,734 common shares.","Approved adjournment proposal to allow sufficient votes on other proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68011,"accession_number":"0001493152-26-022710","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2026-05-13T20:05:25+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dermata Therapeutics Q1 2026: cash $6.9M; R&D spend down to $0.4M; DTC skincare launch planned mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents $6.9M as of Mar 31, 2026, down from $7.5M at Dec 31, 2025; net ATM proceeds of $2.0M.","R&D expenses fell to $0.4M from $1.3M YoY, reflecting reduced clinical spending; SG&A rose to $1.5M from $1.1M.","Announced Tome skincare brand for DTC; first product (Foundational Treatment) expected to launch mid-2026.","Hired Kyra Peckaitis as VP of Marketing to lead Tome brand; cash expected to fund operations into Q1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109986,"accession_number":"0001493152-26-012991","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dermata Therapeutics pivots to DTC skincare; reports year-end 2025 cash of $7.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Strategic pivot from prescription derm to direct-to-consumer skincare brand Tome; first product launch mid-2026.","Cash and equivalents $7.5M at Dec 31, 2025 ($3.2M prior year); funded into Q1 2027.","Raised $15.4M gross in 2025/early 2026 including $4.125M private placement with insider participation.","R&D expenses fell to $2.9M from $8.2M as STAR-1 acne study completed; SG&A up to $4.8M on marketing.","Hired Kyra Peckaitis as VP Marketing; withdrew XYNGARI IND despite positive Phase 3 data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109985,"accession_number":"0001493152-26-008037","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Mary Fisher resigns from Dermata board, effective March 31, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignation due to her employer being acquired; no longer permitted to serve on board.","No disagreement with company or management cited.","Board size to decrease from eight to seven after resignation effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109984,"accession_number":"0001493152-26-004905","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Dermata Therapeutics dismisses Baker Tilly, appoints CBIZ CPAs as new auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Baker Tilly dismissed as independent auditor effective January 31, 2026.","CBIZ CPAs (formerly Mayer Hoffman McCann) appointed February 2, 2026.","No disagreements with Baker Tilly on accounting principles or disclosures.","Baker Tilly's prior reports included a going-concern explanatory paragraph.","CBIZ CPAs previously served as Dermata's auditor from 2016 to 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109983,"accession_number":"0001493152-26-003715","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dermata increases ATM offering capacity by $705K; previously sold $3.45M under same program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to increase maximum aggregate offering under ATM by $705,000.","Prior sales under the June 2024 H.C. Wainwright ATM agreement totaled $3,454,390.","ATM program covers common stock issuances; legal opinion filed as Exhibit 5.1.","No change in business fundamentals; routine capital access expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126568,"accession_number":"0001493152-25-029364","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Dermata raises $4.1M (up to $12.4M) in private placement at $2.04/share for OTC acne kit launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.1M upfront; potential additional ~$8.3M from full warrant exercise for total up to $12.4M.","Issued 2.02M shares (or pre-funded warrants) plus series C and D warrants for 2.02M shares each at $2.04 exercise price.","Company insiders, including CEO/CFO, purchased $1.5M of shares and warrants (735K shares and 1.47M warrants).","Net proceeds ~$3.7M; intended for OTC acne kit launch (mid-2026) and general corporate purposes, including R&D.","Amended 120,734 outstanding warrants from Jan 2025 to $2.04 exercise price from $12.70; expires 5 years from approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126567,"accession_number":"0001493152-25-023942","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Dermata terminates Villani license, pivots to OTC skin care","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated license agreement with Villani Inc.; effective 90 days after Nov 17, 2025 notice.","Eliminates future milestone payments of up to $40.5M and single-digit royalties.","Strategic shift: will commercialize OTC skin care; withdrew XYNGARI IND.","License covered exclusive rights to sponge-based products for skin disease treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126566,"accession_number":"0001493152-25-023419","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dermata Therapeutics pivots to OTC; plans acne kit launch mid-2026, reports Q3 cash $4.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents of $4.7M as of Sep 30, 2025; expected to fund operations into Q2 2026.","R&D expenses dropped to $0.5M in Q3 2025 from $2.4M in Q3 2024 as XYNGARI Phase 3 trial concluded.","Strategic pivot to OTC dermatology; first product is a once-weekly acne kit using Spongilla technology, launch mid-2026.","Company plans to sell OTC acne kit directly to consumers, estheticians, and dermatologists for in-office use."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126565,"accession_number":"0001493152-25-021255","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dermata Therapeutics ups ATM stock offering by $1.79M after prior $1.66M sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to increase aggregate ATM offering by $1,792,315 in common stock.","Prior sales under the same ATM agreement totaled $1,662,142.","Agreement with H.C. Wainwright & Co. is dated June 7, 2024.","Legal opinion on the shares being issued is filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143319,"accession_number":"0001493152-25-013815","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Dermata reports statistically significant Phase 3 XYNGARI acne data vs placebo at EADV 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IGA 2-point reduction + clear/almost clear at Week 12: 29.4% XYNGARI vs 15.2% placebo (p<0.001).","Mean inflammatory lesion count change at Week 12: -16.8 XYNGARI vs -13.1 placebo (p<0.001).","Percent change in non-inflammatory lesions at Week 12: 48.3% XYNGARI vs 34.7% placebo (p<0.001).","All secondary endpoints (IGA, inflammatory, non-inflammatory) statistically significant at Weeks 4, 8, and 12.","Data presented at European Academy of Dermatology and Venereology Congress 2025 from ongoing Phase 3 STAR-1 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143318,"accession_number":"0001493152-25-012952","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Dermata pivots to OTC dermatology, withdraws XYNGARI IND, plans acne kit launch mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Strategic shift to prioritize OTC dermatology products sold directly to consumers.","Initial focus on once-weekly acne kit using approved monograph active ingredient and Spongilla technology.","Plans to launch the acne kit in mid-2026 with additional OTC products to follow.","Withdrew its investigational new drug application for XYNGARI with the FDA.","Aims to accelerate commercialization path and reduce regulatory burdens."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143317,"accession_number":"0001641172-25-025405","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Dermata Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq non-compliance notice on May 14, 2025 due to bid price below $1.00.","Requested hearing; granted exception until August 14, 2025 to demonstrate compliance.","On August 22, 2025, staff confirmed compliance with Minimum Bid Price Requirement; matter closed.","Common stock (DRMA) and warrants (DRMAW) remain listed on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143316,"accession_number":"0001641172-25-023570","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dermata reports positive Phase 3 STAR-1 data, Q2 2025 cash $6.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["XYNGARI™ Phase 3 STAR-1 met all three co-primary endpoints with statistical significance at weeks 4 and 12.","Raised $8.8M gross proceeds in H1 2025; cash $6.5M at June 30, expected to fund operations into Q2 2026.","R&D expenses $0.6M in Q2 2025 vs $2.0M in Q2 2024, decrease due to STAR-1 completion.","G&A expenses $1.2M in Q2 2025 vs $0.9M in Q2 2024; increase from compliance and personnel costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143315,"accession_number":"0001641172-25-021501","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Dermata Therapeutics to effect 1-for-10 reverse stock split effective August 1, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:10 ratio effective 12:01 a.m. ET on August 1, 2025.","Every ten outstanding common shares convert to one share; no fractional shares (cash in lieu).","CUSIP changes to 249845504; trading on Nasdaq on split-adjusted basis expected August 1.","Board authorized split ratio range of 1:2 to 1:30 at July 15 annual meeting; Board selected 1:10.","Outstanding stock options and warrants will be adjusted proportionally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143314,"accession_number":"0001641172-25-019760","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Dermata Therapeutics stockholders approve reverse stock split and director elections at 2025 meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Mary Fisher and Andrew Sandler as Class I directors for three-year terms.","Ratified Baker Tilly US, LLP as independent auditor for FY2025 with 3,229,829 votes for.","Approved issuance of shares underlying warrants from Jan 2025 SPA and March 2025 inducement letter (over 20% of outstanding).","Authorized reverse stock split at ratio between 1:2 and 1:30, with board to determine exact ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143313,"accession_number":"0001641172-25-018042","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq Panel grants Dermata Therapeutics exception until Aug 14, 2025 to meet minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received Nasdaq delisting notice on May 14, 2025 for failing minimum $1.00 bid price over 30 consecutive days.","Hearings Panel granted exception through August 14, 2025 to demonstrate compliance; suspension stayed during hearing process.","Dermata will seek shareholder approval for reverse stock split at July 15, 2025 annual meeting to regain compliance.","If compliance not achieved or other listing requirements unmet, common stock (DRMA) and warrants (DRMAW) may be delisted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161458,"accession_number":"0001641172-25-013823","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Dermata Therapeutics changes auditor to Baker Tilly after Moss Adams merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Moss Adams merged into Baker Tilly US, LLP effective June 3, 2025; audit committee approved Baker Tilly as successor.","No disagreements with Moss Adams on accounting principles or audit scope for FY2024, FY2023, or interim period.","Prior audit reports included a going concern uncertainty paragraph; no adverse or modified opinions.","Moss Adams provided a letter agreeing with the statements, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161457,"accession_number":"0001641172-25-011873","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Dermata initiates XYNGARI drug product manufacturing; Phase 3 STAR-2 trial expected Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Manufacturing for XYNGARI drug product initiated for Phase 3 STAR-2 trial; trial start expected Q4 2025.","Topline data from STAR-2 expected H1 2027; patients can rollover into 9-month extension study.","NDA filing for XYNGARI anticipated in H1 2028 after extension study completion by end of Q4 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161456,"accession_number":"0001641172-25-011286","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dermata Therapeutics faces Nasdaq delisting for minimum bid price; plans hearing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Regained compliance with Nasdaq stockholders' equity requirement on May 14, 2025.","Received notice of non-compliance with $1.00 minimum bid price; securities subject to delisting.","Reverse stock split within past year triggers accelerated delisting; suspension possible May 23, 2025.","Company plans to request hearing by May 21, 2025 to stay suspension pending panel decision.","No assurance compliance plan will be accepted; delisting risk remains if plan fails."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161455,"accession_number":"0001641172-25-010112","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dermata: XYNGARI Phase 3 STAR-1 acne trial meets co-primary endpoints; cash $9.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XYNGARI Phase 3 STAR-1 achieved statistically significant results on all co-primary endpoints at all time points vs placebo.","Entered clinical trial collaboration with Revance to study DMT410 with DAXXIFY for axillary hyperhidrosis.","Raised $8.8M gross proceeds from private placement and warrant inducement financings in Q1 2025.","Cash and equivalents $9.7M as of March 31, 2025, up from $3.2M; expected to fund operations into Q1 2026.","R&D expenses $1.3M, G&A $1.1M; operating cash burn $1.9M in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161454,"accession_number":"0001654954-25-004265","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dermata's XYNGARI Phase 3 trial shows stat sig benefit at 4 weeks in moderate-to-severe acne","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IGA treatment success: 11.9% XYNGARI vs 6.2% placebo (p<0.05) at week 4, after 4 weekly doses.","Inflammatory lesion count mean change: -11.4 XYNGARI vs -8.6 placebo (p<0.001).","Non-inflammatory lesion count mean change: -12.4 XYNGARI vs -8.8 placebo (p<0.001).","Data support earlier positive week 12 topline results for all primary endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179621,"accession_number":"0001654954-25-003552","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Dermata raises ~$6.2M via warrant exercise at reduced price; issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["4,834,470 existing warrants exercised at reduced price of $1.284/share, yielding $6.2M gross proceeds.","New Series A warrants (5-year term) and Series B warrants (18-month term) issued, each exercisable at $1.284.","New warrants require shareholder approval per Nasdaq Rule 5635(d); exercise limited to 4.99% (or 9.99%) ownership.","H.C. Wainwright acted as exclusive financial advisor; fees include 7% cash plus 338,412 HCW warrants at $1.605.","Company plans to use net proceeds for general corporate purposes including R&D and clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179620,"accession_number":"0001654954-25-003372","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dermata's XYNGARI Phase 3 acne trial meets all primary endpoints with statistical significance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["STAR-1 achieved all three primary endpoints: IGA success 29.4% vs 15.2% placebo (p<0.001).","Inflammatory lesion count reduced by 16.8 vs 13.1 (p<0.001); non-inflammatory by 17.3 vs 12.4 (p<0.001).","XYNGARI safe and well tolerated; no serious treatment-related adverse events.","Plans to initiate second Phase 3 STAR-2 trial in H2 2025, followed by NDA submission if positive.","CEO cites potential for partnership discussions; over 30 million U.S. acne patients annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179619,"accession_number":"0001654954-25-003305","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dermata Therapeutics receives Nasdaq delisting notice for failing minimum stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Dermata on March 25, 2025, of non-compliance with $2.5M minimum stockholders' equity rule.","Company reported stockholders' equity of $1.6M as of Dec 31, 2024, below required threshold.","Dermata has 45 days, until May 9, 2025, to submit a plan; possible extension to Sept 21, 2025.","Securities continue trading on Nasdaq while company evaluates options to regain compliance.","If plan rejected or compliance not regained, delisting proceedings may commence; hearing available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179618,"accession_number":"0001654954-25-002886","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dermata reports FY2024 cash burn; Phase 3 STAR-1 topline expected by end of March 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $3.2M as of Dec. 31, 2024, down from $7.4M; expects funding into Q3 2025 after $2.55M Jan. 2025 PIPE.","R&D expense $8.2M in 2024 vs $4.1M in 2023, driven by $4.9M increase in Phase 3 STAR-1 clinical trial costs.","Topline results from XYNGARI Phase 3 STAR-1 acne trial expected by end of March 2025.","Entered Clinical Trial Collaboration Agreement with Revance (Crown Laboratories) to study DMT410 with DAXXIFY for hyperhidrosis.","G&A expense $4.3M in 2024 vs $4.0M in 2023, primarily due to increased audit fees from auditor change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179617,"accession_number":"0001654954-25-000681","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Dermata raises $2.55M private placement at $1.27/unit with insider participation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $2.55M; net ~$2.4M from 2,007,880 shares (or pre-funded warrants) and same number of warrants.","Warrants exercisable at $1.27/share upon stockholder approval and expire five years later.","Insiders (CEO, CFO, board) purchased ~$1.55M of offering at same $1.27/unit price.","Net proceeds plus cash expected to fund operations into Q3 2025.","H.C. Wainwright served as placement agent; resale registration statement to be filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179616,"accession_number":"0001654954-25-000570","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Dermata and Revance enter clinical trial collaboration for Xyngari with Daxxify in hyperhidrosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dermata and Revance will collaborate on a Phase 2a trial of topical Xyngari with Daxxify for moderate-to-severe axillary hyperhidrosis.","Trial expected to enroll ~48 patients across US sites; randomized 1:1:1:1, double-blind, placebo-controlled, 16-week evaluation.","Primary endpoints: ≥50% reduction in gravimetric sweat, absolute change in sweat production, and sweat <50mg.","If successful, parties may explore additional indications; Xyngari is currently in Phase 3 for acne; Daxxify approved for glabellar lines and cervical dystonia.","Potential to be first approved needle-free intradermal delivery of a botulinum toxin product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196370,"accession_number":"0001654954-24-014289","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dermata nears completion of DMT310 Phase 3 enrollment; Q3 2024 cash at $6.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment in DMT310 Phase 3 STAR-1 acne trial expected to complete by end of 2024; topline results Q1 2025.","Cash and equivalents of $6.1M at Sep 30, 2024; expected to fund operations into Q2 2025.","Raised $7.8M in gross proceeds during 2024, including $5.1M in Q3 2024.","R&D expenses $2.4M in Q3 2024, up from $0.9M due to STAR-1 clinical trial costs.","G&A expenses $0.8M in Q3 2024, down from $0.9M in Q3 2023 on lower insurance costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212679,"accession_number":"0001654954-24-012031","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Dermata raises $3.5M gross in private placement; expects cash runway into Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $3.5M from 1,912,569 shares/pre-funded warrants + Series A & B warrants at $1.83/unit.","Net proceeds ~$3.0M after placement agent fees; H.C. Wainwright acted as exclusive agent.","Series A warrants (5.5 yr term) and Series B warrants (18 mo term) each exercisable at $1.58/share.","Including prior raises, total $7.8M gross since May 2024; operations funded into Q2 2025.","Proceeds for general corporate purposes including R&D, clinical trials, and licensing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212678,"accession_number":"0001654954-24-010104","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dermata Therapeutics reports Q2 2024 results; DMT310 Phase 3 trial enrollment over 50%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net cash $4.9M at June 30, 2024, down from $7.4M at Dec 31, 2023; expects to fund ops into Q4 2024.","Raised $2.3M in net proceeds from May 2024 warrant inducement financing.","R&D expenses $2.0M in Q2 2024 vs. $0.8M in Q2 2023 due to STAR-1 trial costs.","DMT310 Phase 3 STAR-1 trial enrolled over 50% of patients; topline data expected Q1 2025.","DMT410 partnership discussions ongoing for topical botulinum toxin delivery."],"consensus_eps_estimate":-2.958,"consensus_eps_actual":-106.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212677,"accession_number":"0001654954-24-009903","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dermata Therapeutics ups ATM offering by $505K to $1.66M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased maximum aggregate offering price under ATM agreement with H.C. Wainwright by $505,000 to $1,662,761.","Previously sold $1,157,247.99 of common stock under the June 7, 2024 Sales Agreement.","Additional $505,000 of shares authorized under the current prospectus supplement.","Legal opinion on share legality filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231702,"accession_number":"0001654954-24-007532","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dermata Therapeutics enters ATM equity facility for up to ~$1.16M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM Agreement with H.C. Wainwright for at-the-market issuance of common stock up to $1,157,761 aggregate market value.","Commission rate 3.0% of gross sales price; expense reimbursement up to $70,000 plus periodic due diligence fees.","Company has no obligation to sell; sales at prevailing market prices on Nasdaq under effective shelf registration statement.","Offering terminates upon sale of all shares or earlier termination by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231701,"accession_number":"0001654954-24-007369","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Dermata regains Nasdaq minimum bid price compliance; delisting risk resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 4, 2024 that company is in compliance with $1.00 minimum bid price requirement.","Previously failed to comply in Nov 2023 and received a 180-day extension through Nov 11, 2024.","Compliance regained ahead of extension deadline; matter closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231700,"accession_number":"0001654954-24-006912","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Dermata Therapeutics regains Nasdaq compliance with publicly held shares rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on May 20, 2024 for failing Rule 5550(a)(4) requiring at least 500,000 publicly held shares.","Provided additional information and as of May 24, 2024, the Company has regained compliance and the matter is closed.","No further action required; common stock (DRMA) and warrants (DRMAW) remain listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231699,"accession_number":"0001654954-24-006608","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["1.01","3.02","3.03","9.01"],"status":"ready","headline":"Dermata raises $2.66M via immediate exercise of warrants at reduced price; issues new warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercise of 516,336 warrants at reduced exercise price of $5.16 per share for cash gross proceeds of ~$2.66M.","Issues new Series A warrants for 601,174 shares (exercise price $4.91, 5.5-year term) and Series B warrants for 431,498 shares (exercise price $4.91, 24-month term).","H.C. Wainwright acts as placement agent; receives 7% cash fee plus 36,144 placement agent warrants at $6.45 exercise price.","Net proceeds for general corporate purposes including R&D, clinical trials, and working capital.","Closing expected on or about May 21, 2024; resale registration statement to be filed for new warrant shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231698,"accession_number":"0001654954-24-006396","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dermata Therapeutics Q1 2024 net loss $3.1M; cash runway into Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $4.7M as of March 31, 2024, down from $7.4M at Dec 31, 2023.","Net loss of $3.1M for Q1 2024; R&D expenses rose to $1.6M on STAR-1 trial costs.","STAR-1 Phase 3 acne trial enrollment on track for completion by end of 2024; topline data expected Q1 2025.","Partnership discussions ongoing for DMT410 topical botulinum toxin; Japanese patent issued for hyperhidrosis.","Company expects current cash to fund operations only into Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231697,"accession_number":"0001654954-24-006312","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Dermata gets 180-day Nasdaq extension; files 1:15 reverse stock split to regain compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq extension until November 11, 2024 to meet $1.00 minimum bid price.","Reverse stock split (1:15) effective May 16, 2024 to increase per-share price.","Nasdaq warned delisting if compliance not regained by the November deadline.","Company cautions no assurance of regaining compliance or meeting other listing rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231696,"accession_number":"0001654954-24-006133","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Dermata Therapeutics to effect 1:15 reverse stock split on May 16, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders authorized reverse split ratio between 1:5 and 1:30; Board selected 1:15 on May 8.","Every 15 existing shares convert to 1 share; no fractional shares, cash paid in lieu.","CUSIP changes to 249845405; trading on Nasdaq on split-adjusted basis expected May 16.","Outstanding options and warrants adjusted proportionally; par value and authorized shares unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231695,"accession_number":"0001654954-24-005715","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Dermata shareholders approve reverse stock split (1:5-1:30) and equity plan expansion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split at ratio from 1:5 to 1:30, exact ratio to be set by Board.","Equity plan amended to increase share reserve from 629,069 to 1,198,951 and raise annual evergreen to 5%.","Three Class III directors elected: Proehl, Wierenga, and Scott.","Ratified Moss Adams LLP as auditor for FY2024.","Adjournment proposal also approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250005,"accession_number":"0001654954-24-003500","cik":1853816,"company_name":"Dermata Therapeutics, Inc.","ticker":"DRMA","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dermata Therapeutics reports FY 2023 net loss; cash runway into Q3 2024; Phase 3 acne trial underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $7.4M as of Dec 31, 2023 vs $6.2M in 2022; expects to fund ops into Q3 2024.","Net proceeds of $7.6M from three 2023 financings partially offset $6.4M cash used in operations.","R&D expenses $4.1M in 2023 (down from $5.7M in 2022) due to lower clinical costs offset by CMC for Phase 3.","Enrollment initiated in DMT310 Phase 3 STAR-1 acne trial in Q4 2023; topline results expected Q1 2025.","Japanese patent issued for DMT410 for hyperhidrosis; partnership discussions ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5228786.016260163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}